Aspirin Use and Risk of Hepatocellular Carcinoma in Hepatitis B
Menée à Taïwan auprès de 10 615 patients atteints d'une hépatite B chronique (72,4% d'hommes, âge moyen : 58,8 ans), cette étude analyse l'association entre une prise quotidienne d'aspirine et le risque de carcinome hépatocellulaire lié au virus de l'hépatite B
Liver cancer (hepatocellular carcinoma [HCC]) incidence and mortality rates have been increasing in most countries for several decades. Currently, HCC is the second most common cause of cancer-related death in the world and represents the fastest rising cause of cancer-related deaths in the United States. Chronic hepatitis B virus (HBV) and hepatitis C virus are the primary underlying causes of HCC, with contributions from alcohol, tobacco, aflatoxin, obesity, and metabolic syndrome. In patients with chronic hepatitis C virus, the risk of HCC can be reduced rapidly with short-term, direct-acting antiviral medications. In chronic HBV, oncogenesis starts with viral DNA integration into the genome of host hepatocytes that induces a cascade of host responses, including cell injury, necrosis, and angiogenesis, reflected clinically by the levels of serum alanine aminotransferase and HBV DNA, both of which are predictors of HCC.
JAMA Internal Medicine , commentaire, 2018